Drugs / VOX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02202980 | Aug 2014 → Mar 2016 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VOX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02202980 ↗ |
| Action | Inhibit | “the NS3/4A protease inhibitor GS-9857” PMID 27240903 ↗ May 2016 |
| Route | Oral | “100 mg tablet administered orally once daily with food” NCT02202980 ↗ |